T-DXd
Gastric Cancer
Trastuzumab deruxtecan in HER2-positive stomach or gastroesophageal junction cancer: A plain language summary of the DESTINY-Gastric02 study
Van Cutsem E.
Future Oncol. 2025 Dec;21(29):3691-3700. doi: 10.1080/14796694.2025.2567230.
Edoxaban
Cardiovascular - AF
Edoxaban dose adjustment and age-associated outcomes in patients with atrial fibrillation post-transcatheter aortic valve replacement
Van Mieghem NM, Chen C, Hengstenberg C, et al.
JACC Adv. 2025 Nov 19;4(12):102329. doi: 10.1016/j.jacadv.2025.102329.
T-DXd
Breast Cancer
Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03
Saura C, Cortés J, Modi S, et al.
Ann Oncol. 2026 Mar;37(3):353-363. doi: 10.1016/j.annonc.2025.11.007.
HER3-DXd
Breast Cancer
Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial
Bartsch R, Marhold M, Garde-Noguera J, et al.
Lancet Oncol 2025; 26: 1467–78.
Pipeline Compounds
Tumor-agnostic
DS-3939a: A TA-MUC1-directed antibody-drug conjugate with broad anti-tumor activity
Takano K, Yukiura M, Takahashi K, et al.
Mol Cancer Ther. 2025 Jul 10. doi: 10.1158/1535-7163.MCT-24-0666.
Pipeline Compounds
Hematology
Novel anti-GARP antibody DS-1055a augments anti-tumor immunity by depleting highly suppressive GARP+ regulatory T cells
Satoh K, Kobayashi Y, Fujimaki K, et al.
Int Immunol. 2021 Jul 23;33(8):435-446. doi: 10.1093/intimm/dxab027.
Pipeline Compounds
Hematology
Bidirectional anti-tumor and immunological strategies by targeting GARP-TGF-β axis in adult T-cell leukemia/lymphoma
Suzuki K, Kusayanagi S, Kuze Y, et al.
Leukemia. 2025 Oct;39(10):2465-2476. doi: 10.1038/s41375-025-02725-0.
T-DXd
Lung Cancer
Trastuzumab deruxtecan for ERBB2-mutant metastatic non-small cell lung cancer with or without brain metastases: A secondary analysis of randomized clinical trials
Jänne PA, Planchard D, Goto K, et al.
JAMA Netw Open. 2025 Nov 3;8(11):e2543107. doi: 10.1001/jamanetworkopen.2025.43107.
Valemetostat
Hematology
Concentration-QTc analysis of valemetostat in patients with hematologic malignancies
Tachibana M, Poland B, Kakurai Y, Chen Y, Li C, Lau Y.
Clin Transl Sci. 2025 Nov;18(11):e70391. doi: 10.1111/cts.70391.
T-DXd
Breast Cancer
Trastuzumab deruxtecan plus pertuzumab for HER2-positive metastatic breast cancer
Tolaney SM, Jiang Z, Zhang Q, Barroso-Sousa R, et al.
N Engl J Med. 2026 Feb 5;394(6):551-562. doi: 10.1056/NEJMoa2508668.